HIMSS 2024
SOPHiA GENETICS™ thrilled to be back at this year’s Healthcare Information and Management Systems Society annual meeting. Join us from March 11th – 15th in Orlando, Fl, where more than 33K health professionals from around the globe will gather to discuss how we...
SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024
BOSTON, United States and ROLLE, Switzerland, February 20, 2024 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full-year...
LBx Summit 2024
SOPHiA GENETICS is excited to be part of the 8th Annual Liquid Biopsy for Precision Oncology Summit, held in person in San Diego, CA, USA, from February 28 to March 1, 2024. You will have the chance to chat with our experts and learn more about our collaboration...
Advancements in Clinical Management of Ovarian Cancer: Integrating HRD and BRCA Status With a Decentralized Solution
The webinar aims to provide a comprehensive overview of the latest advancements in the clinical management of high-grade ovarian cancer, with a focus on incorporating information regarding homologous recombination deficiency (HRD) and BRCA statuses obtained through...
Article Spotlight: GIInger™ supports prediction of HRD and PARPi response from shallow genomic profiles
Discover how a deep learning algorithm, GIInger™, leverages low-coverage sequencing data to identify homologous recombination deficiency (HRD)-induced genomic instability.
SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain
SOPHiA GENETICS and AstraZeneca Spain expand HRD testing program to support molecular diagnosis of ovarian cancer in Spain Boston, MA, Rolle, Switzerland and Madrid, Spain, February 7, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a...
Medicinski fakultet Univerziteta u Beogradu is Live with SOPHiA GENETICS
The University will use the SOPHiA DDM™ Platform to enhance blood cancer testing and research Boston, MA and Rolle, Switzerland, January 31, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced...
Technical Note: Navigating overfitting during machine learning model development
We’re often asked how we avoid overfitting when developing predictive machine learning models for clinical research. This technical note explains how.
SOPHiA GENETICS Supports Genetic Testing in Brazil
The company announced Bioma4me has implemented SOPHiA DDM™ to support its rare disorder testing capabilities Boston, MA and Rolle, Switzerland, January 25, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader...
SOPHiA GENETICS Named in Built In’s Esteemed 2024 Best Places To Work Awards
Boston, MA – January 22, 2024 — SOPHiA GENETICS announced today that it was honored by Built In on its 2024 Best Places To Work Awards. SOPHiA GENETICS was named on the Boston mid-size company and overall best places to work lists. The annual awards program...
SOPHiA GENETICS Enhances RareCyte Precision Biology Services Portfolio
RareCyte will use the SOPHiA DDM™ Platform to support its oncology testing panel BOSTON MA and Rolle, Switzerland, January 18, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced...
Going beyond HRR mutations: A deep-learning approach on HRD detection in ovarian cancer
Going beyond HRR mutations: A deep-learning approach on HRD detection in ovarian cancer Homologous recombination deficiency (HRD) is an important prognostic and predictive biomarker in ovarian cancer. It is assessed by combining information from homologous...
Accelerating access to precision oncology with decentralized MSK solutions
SOPHiA GENETICS is collaborating with Memorial Sloan Kettering Cancer Center (MSK) to decentralize their advanced precision oncology tools – MSK-ACCESS® for liquid biopsy and MSK-IMPACT® for comprehensive genomic profiling (CGP). By combining the clinical expertise...
SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India
SOPHiA GENETICS technology helps advance cancer research across India SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic solutions for breakthroughs in personalized cancer care in India Boston, MA and Rolle, Switzerland, January 15,...
